Chemokines and lung cancer

Abstract

Li Guodong, Ouyang Weiwei, Su Shengfa, Ma Zhu, Li Qingsong, Wang Yu, Lu Bing. Chemokines and lung cancer[J]. Journal of International Oncology, 2016, 43(10): 787-790.

［1］ Rossi D, Zlotnik A. The biology of chemokines and their receptors［J］. Annu Rev Immunol, 2000, 18: 217242. ［2］ Wrnle M, Schmid H, Merkle M, et al. Effects of chemokines on proliferation and apoptosis of human mesangial cells［J］. BMC Nephrol, 2004, 5(5): 8. DOI: 10.1186/1471236958. ［3］ Beider K, Abraham M, Begin M, et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth［J］. PLoS One, 2009, 4(4): e5125. DOI: 10.1371/journal.pone.0005125. ［4］高永静, 张志军, 曹德利. 趋化因子介导的神经炎症反应和神经病理性疼痛［J］. 中国细胞生物学学报, 2014, 3(3): 297307. ［5］张静, 邓向红. 趋化因子与中枢神经系统感染［J］. 临床医学工程, 2014 (5): 668669, 672. DOI: 10.3969/j.issn.16744659.2014.05.0668. ［6］段冬冬, 宋泽庆. 趋化因子与结核性胸膜炎［J］. 医学理论与实践, 2014, 27(17): 22632265. ［7］刘相良, 原铭贞, 刘笑玎, 等. 趋化因子及其受体在急性肺损伤中作用的研究进展［J］. 吉林大学学报(医学版), 2014(4): 908912. DOI: 10.13481/j.1671587x.20140445. ［8］ Molina JR, Yang P, Cassivi SD, et al. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship［J］. Mayo Clin Proc, 2008, 83(5): 584594. DOI: 10.4065/83.5.584. ［9］ Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin′s lymphoma microenvironment and its role in promoting tumour growth and immune escape［J］. J Pathol, 2010, 221(3): 248263. DOI: 10.1002/path.2711. ［10］ Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS1101 (CAL101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma［J］. Blood, 2012, 119(8): 18971900. DOI: 10.1182/blood201110386763. ［11］杨璐, 李恒平, 刘振华, 等. 趋化因子与炎症、前列腺癌的关系的研究［J］. 现代预防医学, 2015, 42(5): 952956. ［12］唐威, 李劲东. 甲状腺癌组织中趋化因子4受体和趋化因子7受体的表达情况及临床病理意义［J］. 标记免疫分析与临床, 2015, 22(5): 450452, 473. DOI: 10.11748/bjmy.issn.10061703.2015.05.026. ［13］ Mukaida N, Baba T. Chemokines in tumor development and progression［J］. Exp Cell Res, 2012, 318(2): 95102. DOI: 10.1016/j.yexcr.2011.10.012. ［14］ Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human nonsmall cell lung cancer cells［J］. PLoS One, 2011, 6(6): e21119. DOI: 10.1371/journal.pone.0021119. ［15］ Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 prevents apoptosis via the ERK pathway in human nonsmall cell lung cancer cells［J］. PLoS One, 2012, 7(3): e33262. DOI: 10.1371/journal.pone.0033262. ［16］ Imai H, Sunaga N, Shimizu Y, et al. Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer［J］. Int J Immunopathol Pharmacol, 2010, 23(1): 153164. ［17］ Wu FY, Fan J, Tang L, et al. Atypical chemokine receptor D6 inhibits human nonsmall cell lung cancer growth by sequestration of chemokines［J］. Oncol Lett, 2013, 6(1): 9195. DOI: 10.3892/ol.2013.1358. ［18］ Hu W, Liu Y, Zhou W, et al. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro［J］. PLoS One, 2014, 9(6): e99056. DOI: 10.1371/journal.pone.0099056. ［19］ Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma［J］. Cancer Res, 2013, 73(2): 571582. DOI: 10.1158/00085472.CAN120263. ［20］ Gupta P, Sharma PK, Mir H, et al. CCR9/CCL25 expression in nonsmall cell lung cancer correlates with aggressive disease and mediates key steps of metastasis［J］. Oncotarget, 2014, 5(20): 1017010179. DOI: 10.18632/oncotarget.2526. ［21］ Ploenes T, Scholtes B, Krohn A, et al. CCchemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential［J］. PLoS One, 2013, 8(1): e53068. DOI: 10.1371/journal.pone.0053068. ［22］ Dai X, Mao Z, Huang J, et al. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of nonsmall cell lung cancer in vitro［J］. Oncol Lett, 2013, 5(1): 277282. DOI: 10.3892/ol.2012.960. ［23］ Choi YH, Burdick MD, Strieter BD, et al. CXCR4, but not CXCR7, discriminates metastatic behavior in nonsmall cell lung cancer cells［J］. Mol Cancer Res, 2014, 12(1): 3847. DOI: 10.1158/15417786.MCR120334. ［24］ Xie S, Zeng W, Fan G, et al. Effect of CXCL12/CXCR4 on increasing the metastatic potential of nonsmall cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression［J］. Oncol Lett, 2014, 7(4): 941947. DOI: 10.3892/ol.2014.1837. ［25］ Wang L, Wang Z, Liu X, et al. Highlevel CXC chemokine receptor type 4 expression correlates with brainspecific metastasis following complete resection of nonsmall cell lung cancer［J］. Oncol Lett, 2014, 7(6): 18711876. DOI: 10.3892/ol.2014.1979. ［26］ Kee JY, Arita Y, Shinohara K, et al. Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo［J］. Mol Clin Oncol, 2013, 1(1): 3540. DOI: 10.3892/mco.2012.30. ［27］ Baratelli F, Takedatsu H, Hazra S, et al. Preclinical characterization of GMP grade CCL21gene modified dendritic cells for application in a phase Ⅰ trial in nonsmall cell lung cancer［J］. J Transl Med, 2008, 6: 38. DOI: 10.1186/14795876638. ［28］ Kar UK, Srivastava MK, Andersson A, et al. Novel CCL21vault nanocapsule intratumoral delivery inhibits lung cancer growth［J］. PLoS One, 2011, 6(5): e18758. DOI: 10.1371/journal.pone.0018758. ［29］ Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential［J］. Theranostics, 2013, 3(1): 2633. DOI: 10.7150/thno.4922.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[6]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[7]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[8]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin.Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.
[9]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[10]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[11]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[12]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[13]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model[J]. Journal of International Oncology, 2022, 49(9): 532-536.
[14]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying.Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses[J]. Journal of International Oncology, 2022, 49(8): 459-463.
[15]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments